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Purpose
To estimate the current cancer burden in Korea, newly diagnosed cancer cases and cancer
incidence rates were calculated for the years 2003�2005. 
Materials and Methods
The cancer incidence cases and rates were calculated from the Korea National Cancer In-
cidence Database. Crude and age-standardized incidence rates were calculated by gender
for specified cancer sites in 5-year age groups.
Results
From 2003 to 2005, 398,824 cases of cancer were newly diagnosed in Korea (218,856 in men
and 179,968 in women). For all sites combined, the crude incidence rate (CR) was 300.0 and
248.2 for men and women and the age-standardized incidence rate (ASR) was 297.0 and
191.2 per 100,000, respectively. Among men, five leading cancers were stomach (CR 66.0,
ASR 64.2), lung (CR 48.5, ASR 50.3), liver (CR 44.9, ASR 42.1), colon and rectum (CR 37.9, ASR
37.2), and prostate cancer (CR 12.7, ASR 13.8). Among women, five leading cancers were
breast (CR 37.3, ASR 29.0), thyroid (CR 36.2, ASR 28.8), stomach (CR 34.1, ASR 25.4), colon and
rectum (CR 28.0, ASR 21.1), and lung cancer (CR 17.9, ASR 12.8). In the 0�14-year-old group,
leukemia was the most common in both sexes; in the 15�34 group, the most common
cancer was stomach cancer for men and thyroid cancer for women; in the 35�64 group,
stomach cancer for men and breast cancer for women; among those 65 and over, lung
cancer for men and stomach cancer, for women, respectively.  
Conclusion
The cancer incidence rates have increased in recent years, and more cancers are expected
to develop as Korea is quickly becoming an aged society. The cancer incidence statistics in
this report can be used as an important source to effectively plan and evaluate the cancer
control program in Korea. 
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I n t r o d u c t i o n
Cancer is the leading cause of death in Korea. To estimate the
cancer burden, a cancer registry is an essential component for
planning and monitoring any national cancer control program (1).
Since the Korea National Cancer Incidence Database (KNCIDB) for
the year 1999 was first constructed in 2003, the Korea Central
Cancer Registry (KCCR) has reported the annual cancer incidence
rates in collaboration with eight regional population-based cancer
registries, site-specific cancer registries, and the National Health
Insurance Corporation (NHIC) (2,3).
This report presents the national cancer incidence rates for 2003
�2005 based on the KNCIDB.
M a t e r i a l s  a n d  M e t h o d s
The KCCR developed a standardized form to identify cancer
cases using hospital discharge records. All malignant neoplasms and
in situ cases are classified according to the International
Classification of Diseases for Oncology, 3rd edition (4) and
converted according to the International Classification of Diseases,
10th edition (5). To improve the completeness of the nationwide
cancer registry data, several sources of data were combined: national
death certification data from the Korea National Statistical Office
(KNSO), medical claims data from the NHIC, and additional
medical record reviews. The KNCIDB is described in detail
elsewhere (2,3). The list of KCCR-registered cases and a list of
cancer cases from claims made through the NHIC for each region
were sent to the regional cancer registries to find missing cases. The
data collection methods at the regional cancer registries were both
passive and active. From 2002 to 2008, we conducted an ad hoc
Site ICD-10
Males Females
Cases* %� CR� ASR§ Cum risk‖ Cases* %� CR� ASR§ Cum risk‖
Lip, mouth, C00�C14 4,625 2.1 6.3 6.1 0.7 1,629 0.9 2.2 1.8 0.2 
and pharynx
Esophagus C15 5,410 2.5 7.4 7.6 1.0 512 0.3 0.7 0.5 0.1 
Stomach C16 48,164 22.0 66.0 64.2 7.7 24,708 13.7 34.1 25.4 2.9 
Colon and rectum C18�C20 27,640 12.6 37.9 37.2 4.5 20,275 11.3 28.0 21.1 2.5 
Liver C22 32,730 15.0 44.9 42.1 4.9 10,686 5.9 14.7 11.2 1.3 
Gallbladder, etc.¶ C23�C24 5,838 2.7 8.0 8.3 1.0 5,884 3.3 8.1 5.8 0.7 
Pancreas C25 5,774 2.6 7.9 8.0 1.0 4,556 2.5 6.3 4.5 0.5 
Larynx C32 3,023 1.4 4.1 4.2 0.5 264 0.1 0.4 0.3 0.0 
Lung C33�C34 35,412 16.2 48.5 50.3 6.1 12,958 7.2 17.9 12.8 1.4 
Breast C50 160 0.1 0.2 0.2 0.0 27,049 15.0 37.3 29.0 2.9 
Cervix uteri C53 -  - - - - 12,104 6.7 16.7 12.8 1.4 
Corpus uteri C54 - - - - - 3,321 1.8 4.6 3.7 0.4 
Ovary C56 - - - - - 4,536 2.5 6.3 5.1 0.5 
Prostate C61 9,260 4.2 12.7 13.8 1.6 - - - - - 
Testis C62 452 0.2 0.6 0.6 0.0 - - - - -
Kidney C64 4,242 1.9 5.8 5.5 0.6 2,004 1.1 2.8 2.2 0.3 
Bladder C67 6,775 3.1 9.3 9.5 1.1 1,709 0.9 2.4 1.7 0.2 
Brain and CNS C70�C72 2,395 1.1 3.3 3.3 0.3 2,127 1.2 2.9 2.6 0.2 
Thyroid C73 4,167 1.9 5.7 4.8 0.5 26,230 14.6 36.2 28.8 2.8 
Hodgkin’s disease C81 357 0.2 0.5 0.5 0.0 153 0.1 0.2 0.2 0.0 
Non-Hodgkin’s C82�C85, 4,777 2.2 6.5 6.3 0.7 3,623 2.0 5.0 4.0 0.4
lymphoma C96 
Multiple myeloma C90 1,083 0.5 1.5 1.5 0.2 955 0.5 1.3 1.0 0.1 
Leukemia C91�C95 3,801 1.7 5.2 5.5 0.5 3,048 1.7 4.2 4.0 0.4 
Others Re.C00�C97 12,771 5.8 17.5 17.8 1.9 11,637 6.5 16.0 12.6 1.3 
All Cancer C00�C97 218,856 100.0 300.0 297.0 30.0 179,968 100.0 248.2 191.2 18.7 
Table 1.  Total number of cancer cases and age-standardized cancer incidence rates by gender in Korea during 2003�2005
*the total number of cases by site, �percentage of all cancers, �crude rate per 100,000 person-years, §the world age-standardized rate per 100,000 person-years, ‖cumulative
risk up to age 74 years, ¶gallbladder and other and unspecified parts of biliary tract.
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nationwide medical record review survey of patients who were
newly diagnosed during 1999�2006, and who were not registered
in either registration system (hospital-based cancer registration and
regional population-based cancer registration).
The KNCIDB was further refined by confirming multiple
primary cancers according to the rules of the International Agency
for Research on Cancer (6). Other duplicated cases were removed
with the help of experts from a variety of fields, such as clinicians,
pathologists, and medical records administrators.
All cancer cases newly diagnosed during 2003�2005 were
included in this study. Approximately 84.4% (336,470 of 398,824
cases) were registered through the KCCR program, while 15.6% of
the cases were collected through the population-based regional
cancer registries, site-specific cancer registries, and other ad hoc
medical records review surveys.
The crude incidence rate (CR) per 100,000 by gender was
calculated for 18 age groups (i.e., 0�4 years, 5�9 years, and
groups of 5-year categories up to 85 years and over) and
standardized to the WHO world standard population (7).
The population used as the denominator to calculate cancer
incidence rates was the midyear population (the population on July
1) in a given year, which was estimated by taking the average of
available population data from the KNSO on December 31 for 2
consecutive years (8). Detailed population was listed in appendix 1.
We calculated several indices to measure the quality of the
Korean cancer registry data: the mortality/incidence (M/I) ratio and
the percentages of microscopic verification (MV%), death
certificate only (DCO%), primary site unknown (PSU%), and age
unknown (Age UNK%) (9). For the M/I ratio, an indicator of data
completeness, the mortality data on cancer by gender, age group,
and site for the same period as the registered cases from the KNSO
were compared to the incidence data from the registry, which are
presented as percentages. The MV%, an indicator of the validity of
the diagnostic information, is the percentage of cases for which the
diagnosis was based on morphological verification of a tissue
specimen. The DCO%, the percentage of cases registered based on
death certificates only, is an index of diagnostic validity. PSU% and
Age UNK% are the percentages of cases registered with unknown
primary sites or unknown age, respectively. The cumulative risk for
developing cancer during a specified time period was computed as
the proportion of initially susceptible individuals in a population
who become incident cases during a given time period, in the
0
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Fig. 1. Age-specific incidence rates of the five
major cancers in males.
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Males Females
Site ICD-10
Cases* MV� DCO� M/I§ Cases* MV� DCO� M/I§
Lip, mouth, and pharynx C00�C14 4,625 92.2 2.5 45.4 1,629 91.1 3.6 34.6 
Esophagus C15 5,410 89.8 4.5 75.1 512 69.7 13.7 77.1 
Stomach C16 48,164 92.7 3.2 46.0 24,708 89.9 4.8 48.2 
Colon and rectum C18�C20 27,640 92.7 2.3 34.4 20,275 90.2 3.2 38.6 
Liver C22 32,730 24.6 6.7 75.8 10,686 23.4 9.1 76.2 
Gallbladder, etc.¶ C23�C24 5,838 55.3 7.7 82.8 5,884 51.6 8.2 80.4 
Pancreas C25 5,774 44.0 8.4 91.7 4,556 37.7 9.3 91.2 
Larynx C32 3,023 88.4 4.4 56.5 264 70.5 17.8 81.1 
Lung C33�C34 35,412 78.7 7.8 83.1 12,958 68.2 12.3 80.9 
Breast C50 160 86.9 9.4 33.1 27,049 97.5 0.9 16.7 
Cervix uteri C53 -  - - - 12,104 95.4 1.3 26.9 
Corpus uteri C54 - - - - 3,321 98.0 0.4 12.8 
Ovary C56 - - - - 4,536 87.1 4.5 44.8 
Prostate C61 9,260 91.2 2.5 28.3 - - - -
Testis C62 452 97.6 0.0 10.4 - - - -
Kidney C64 4,242 83.7 1.9 31.0 2,004 80.4 3.2 29.1 
Bladder C67 6,775 92.1 2.0 30.1 1,709 83.7 5.1 40.7 
Brain and CNS C70�C72 2,395 65.8 10.3 76.4 2,127 59.3 12.1 76.0 
Thyroid C73 4,167 98.4 0.6 7.2 26,230 98.7 0.3 2.7 
Hodgkin’s disease C81 357 99.2 0.8 26.1 153 99.3 0.7 26.8 
Non-Hodgkin’s lymphoma C82�C85, C96 4,777 93.9 3.4 45.2 3,623 93.5 3.4 39.3 
Multiple myeloma C90 1,083 88.7 5.8 74.2 955 84.4 5.4 70.1 
Leukemia C91�C95 3,801 89.5 5.0 64.5 3,048 88.9 5.4 63.5 
Others Re. C00�C97 12,771 83.4 4.9 43.6 11,637 81.6 6.7 40.1 
All cancer C00�C97 218,856 76.8 4.7 56.3 179,968 83.6 4.3 39.4 
Table 4.  Indices of data quality by gender (Units: %)
*the total number of cases by site, �microscopically verified, �death certificate only, §mortality/Incidence ratio, ‖gallbladder and other and unspecified parts of biliary tract.
absence of other competing causes of death. Cumulative risk was
derived from the cumulative rate, which is the sum of each age-
specific rate over each year of age from birth to a defined upper age
limit. In this report, we used 74 years old as the upper age limit.
R e s u l t s
Between 2003 and 2005, 398,824 cancer cases were newly
diagnosed in Korea (218,856 in men and 179,968 in women). For all
sites of cancer, the CRs were 300.0 and 248.2, and the age-
standardized incidence rates (ASRs) were 297.0 and 191.2 per 100,000
for men and women, respectively. The overall cumulative risk for
developing a cancer before the age of 74 was 30.0% for males and
18.7% for females (Table 1). In males, the five leading primary cancer
sites were the stomach (CR 66.0, ASR 64.2), lung (CR 48.5, ASR
50.3), liver (CR 44.9, ASR 42.1), colon and rectum (CR 37.9, ASR
37.2), and prostate (CR 12.7, ASR 13.8). In females, the most common
primary cancer sites were the breast (CR 37.3, ASR 29.0), followed by
the thyroid (CR 36.2, ASR 28.8), stomach (CR 34.1, ASR 25.4), colon
and rectum (CR 28.0, ASR 21.1), and lung (CR 17.9, ASR 12.8).
In the 0�14-year age group, leukemia was the most common
cancer in both genders. For males, stomach cancer was the common
in the 15�64-year age group, while lung cancer was more frequent
in the over 65-year age group. For females, the most common forms
of cancer for each age group were as follows: 15�34 years, thyroid
cancer; 35�64 years, breast cancer; and stomach cancer for age 65
years and older (Tables 2, 3). Fig. 1 and 2 plot the age-specific in-
cidence of the five and seven major cancers in men and women,
respectively. In men, the incidence of the five major cancers
increased gradually with age, while in women, the incidence of
breast and thyroid cancers increased with age until the late 40 s and
early 50 s and then subsequently decreased.
In terms of the quality indices, the KNCIDB showed acceptable
values for the cancer incidence data for 2003�2005 (Table 4). In
particular, the MV% of the diagnosis was 76.8% for men and 83.6%
for women. The DCO% was 4.7% for men and 4.3% for women.
The M/I ratio was 56.3% and 39.4% for men and women,
respectively. The PSU% was 1.4% and 1.5% for the respective
sexes. The Age UNK% was 0% for both men and women.
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D i s c u s s i o n
This report presents the nationwide cancer incidence statistics for
Korea during 2003�2005. Compared to cancer statistics for 1999
�2002 reported in the Cancer Incidence in Five Continents,
Volume IX (10), the crude cancer incidence rates during 2003�
2005 increased by 21.6% (17.9% in men and 26.5% in women).
While these increases might have resulted from improved
completeness and the aging population in Korea during recent years,
these increases in cancer incidence could be real, as the age-
standardized incidence rates have also increased. A possible
explanation for these increases is the change to a Westernized
lifestyle, such as the high consumption of fat and less physical
activity, together with early detection.
In Korean men, stomach, lung, liver, colorectal, and prostate
cancers are the five most common cancers, accounting for two-thirds
of the cancer burden. In Korean women, breast, thyroid, stomach,
colorectal, and lung cancer account for two-thirds of the cancer
burden. In particular, increases in colorectal, thyroid, prostate, and
female breast cancer have been observed. The rapid increase in
thyroid cancer incidence in women might be attributable to improved
diagnostic techniques, leading to the detection of disease that would
have gone undetected previously, rather than a true increase in the
incidence of thyroid cancer, as in the United States (11).
Assessing the quality of the data for completeness and validity is
essential. In particular, completeness is a critically important
component (12). Various methods have been proposed to measure
the completeness of registration. Using the Ajiki method (13), the
completeness of incidence for 2003�2005 in Korea is 94.6%. We
also evaluated the completeness and validity of the incidence data
for 2003�2005 using the indices MV%, DCO%, M/I ratio, PSU%,
and Age UNK%. All of the values for these indices satisfied the
evaluation criteria published in the Cancer Incidence in Five
Continents, Volume IX (14). Here, DCO% was 4.7% for men and
4.3% for women (improved from 6.1% for men and 5.8% for
women during 1999�2002). The PSU% of the KNCIDB (1.4% for
men and 1.5% for women) is relatively low compared to those of
most countries (14). For Age UNK%, which rarely exceeds 1% in
developed countries, only one case with an unknown age occurred
in our data.
Cancer certainly has become a very important public health
concern in Korea, and as Korea becomes an aged society, the cancer
burden will continue to increase. The cancer incidence rates in this
report can be used as an important source to plan and evaluate the
cancer control program in Korea more effectively.
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Appendix 1. Total population* of Korea during 2003�2005 and
the world standard population
Age group (years) Males Females World�
0�4 4,220,902 3,868,110 12,000 
5�9 5,338,078 4,809,133 10,000 
10�14 5,506,384 4,858,316 9,000 
15�19 4,984,741 4,551,485 9,000 
20�24 6,088,538 5,752,891 8,000 
25�29 6,016,597 5,771,690 8,000 
30�34 6,939,159 6,660,742 6,000 
35�39 6,644,702 6,388,685 6,000 
40�44 6,730,105 6,449,713 6,000 
45�49 5,753,694 5,581,927 6,000 
50�54 4,026,381 3,982,377 5,000 
55�59 3,192,517 3,272,964 4,000 
60�64 2,844,844 3,193,546 4,000 
65�69 2,144,762 2,697,956 3,000 
70�74 1,275,400 1,998,495 2,000 
75�79 708,340 1,344,640 1,000 
80�84 376,880 814,313 500 
85� 169,430 518,329 500 
Total 72,961,454 72,515,312 100,000 
*for a given year, the midyear population size was estimated using the average of the
population on december 31 for 2 consecutive years. total population was the sum of
midyear population during a given period, �the world standard population is a
theoretical proportion of the world population used for standardization.
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